Contact us
Facebook
Google+
Twitter
LinkedIn

Home
Company
Our platform
- HLA-G platform
- IVS-3001 – anti-HLA-G CAR T cells
Clinical Trials
Resources
- Glossary
- Invectys publications
News
- Press Releases
- Events
Contact
- Contact us
- Careers

Home
Company
Our platform
- HLA-G platform
- IVS-3001 – anti-HLA-G CAR T cells
Clinical Trials
Resources
- Glossary
- Invectys publications
News
- Press Releases
- Events
Contact
- Contact us
- Careers

Home / Site web réalisé par Acorelis

Site web réalisé par Acorelis

Site web réalisé par Acorelis

Gilles Petitot et Thibaut Lacheray

Latest Articles

Clinical Trials 8 août 2023
FDA Grants Fast Track designation to IVS-3001, Invectys’ CAR-T Cell Therapy in the Treatment of Renal Cell Carcinoma 31 juillet 2023
Invectys Announces Initiation of Phase 1/2a Clinical Trial in Solid Tumors and Change in Leadership 13 juillet 2023
Invectys Receives its Second MATWIN Award 26 mai 2023
Invectys to participate in project Melomanes 29 mars 2023

Founded in 2010 out of the Pasteur Institute, Invectys is a biopharmaceutical company focused on the development of innovative immunotherapy approaches to treat cancer with its headquarters in Houston, Texas and Research & Innovation center in Paris.

Invectys exploits a novel approach to mobilizing and restoring the anti-tumor capacity of the immune system of cancer patients. This allows virtually all cancers to be targeted. Invectys focuses its efforts on two platforms: 1) HLA-G, a powerful immune checkpoint and a tumor specific antigen; 2) the universal tumor antigen telomerase (TERT) that is critical to uncontrolled cell growth.

Menu

Contact us
Legal notices
Press Releases

Contact US

Invectys Inc.
109 North Post Oak Lane,
Suite 600, Houston,
TX 77024, USA

Follow US

Facebook
Google+
Twitter
LinkedIn

Credits

Communication and editorial: Acorelis
Graphic creation and development: 17Pixel.com

Copyright © 2024 Invectys